Overview

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Status:
Recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer

Phase:

Phase 2

Details

Lead Sponsor:

RemeGen Co., Ltd.

Treatments:

Disitamab vedotin